MK-4002(靶向BCMA的T细胞衔接器)治疗复发或难治性多发性骨髓瘤:首次人体、开放标签、1期研究
这项首次人体1期研究评估了三特异性BCMA靶向T细胞衔接器MK-4002在复发或难治性多发性骨髓瘤中的安全性、初步活性和药代动力学。
要点
- 12 mg组总缓解率为63%,初步推荐2期剂量为12 mg。
- 细胞因子释放综合征发生率为30%,多为1-2级。
核心结论
- 12 mg剂量观察到最佳安全性和活性,支持进一步临床评估。
研究设计与样本
- 开放标签、1期、首次人体研究,在法国、西班牙和美国的12个中心开展。
- 纳入97例年龄≥18岁、ECOG评分0-2、既往至少接受三线治疗的复发或难治性多发性骨髓瘤患者。
主要发现
- 97例(100%)发生不良事件,79%发生≥3级不良事件,最常见≥3级不良事件为贫血(34%)、中性粒细胞计数降低(23%)和中性粒细胞减少(19%)。
- 细胞因子释放综合征发生于29例(30%),其中1-2级27例,3级2例(均发生在24 mg剂量后)。
- 药代动力学呈剂量比例,中位半衰期为68小时(范围52-76)。
关键数值与推荐
- 初步推荐2期剂量为目标剂量12 mg。
- 12 mg组总缓解率为63%(95% CI 38-84),其中19例中10例达到非常好的部分缓解或更好。
临床怎么用
- 12 mg剂量可能作为后续临床评估的推荐剂量。
局限性
- 研究为首次人体1期试验,样本量有限,结果需进一步验证。
- 研究仍在进行但已停止招募,数据截止时随访时间有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The optimal treatment strategy for relapsed or refractory multiple myeloma remains unclear. This first-in-human study aimed to evaluate the safety, preliminary activity, and pharmacokinetics of the trispecific B-cell maturation antigen-targeting T-cell engager MK-4002 in relapsed or refractory multiple myeloma. METHODS: This open-label, phase 1 study was conducted at 12 sites (hospitals and cancer centres) in France, Spain, and the USA. Participants were aged 18 years or older, had relapsed or refractory multiple myeloma, an Eastern Cooperative Oncology Group performance status score of 0 to 2, and had received at least three previous therapies. Participants received MK-4002 at doses from 0·005 mg to 24 mg intravenously weekly or every 2 weeks following a dose escalation design. One participant was enrolled per dose level, starting at 0·005 mg. Once an adverse event of grade 2 or worse or a dose-limiting toxicity was observed, the study transitioned to a 3 + 3 dose escalation phase. Initially, dose escalation occurred in fixed-dose cohorts (target dose weekly on day 1 of each cycle). Once a grade 2 or worse cytokine release syndrome event occurred, step-up dosing began (treatment initiated with at least one priming dose on day 1 of cycle 1 followed by the target dose weekly or every 2 weeks). Dose escalation continued until the maximum tolerated dose (MTD), recommended phase 2 dose (RP2D), or both, were identified. Expansion cohorts of up to 15 participants were added to assess regimens and schedules at dose levels considered safe by the Cohort Review Committee. Primary endpoints were safety; MTD, RP2D, or both; and pharmacokinetics. The key secondary endpoint was overall response rate (ORR) per International Myeloma Working Group criteria. Safety was analysed in all participants who received at least one dose of MK-4002. ORR was analysed in all participants who received at least one dose of MK-4002 and had at least one postbaseline disease assessment. This study is registered with ClinicalTrials.gov (NCT04184050) and is ongoing but closed to recruitment. FINDINGS: Between April 21, 2020, and June 28, 2023, 97 participants were enrolled and treated across 17 fixed-dose, stepped-dose, and dose-expansion cohorts. Median age was 69 years (IQR 61-74); 50 participants (52%) were male and 47 (48%) female. Median time since diagnosis was 6·8 years (IQR 4·2-9·9), and participants had received a median of six (IQR 4-8) previous lines of therapy. Median time from first dose to data cutoff was 27·1 months (IQR 15·7-34·3). Dose-limiting toxicities occurred in six participants. The MTD for the fixed dose was established as 2·15 mg and was not reached in the stepped-dose cohorts. Adverse events occurred in 97 participants (100%); 77 (79%) had grade 3 or worse events. The most common grade 3 or worse adverse events were anaemia (33 participants [34%]), neutrophil count decreased (22 participants [23%]), and neutropenia (18 participants [19%]). Serious adverse events occurred in 56 participants (58%). One participant (1%) died due to treatment-related traumatic subdural haematoma. Cytokine release syndrome occurred in 29 participants (30%): grade 1-2 occurred in 27 participants, and grade 3 occurred in two participants (both after a 24 mg dose). MK-4002 exhibited dose-proportional pharmacokinetics with a median half-life of 68 h (range 52-76). ORR was 41% (95% CI 22-61) in the 2·15-6 mg dose group (nine of 27 participants had a very good partial response or better), 63% (38-84) in the 12 mg group (ten of 19 participants had a very good partial response or better), and 48% (31-67) in the 24 mg dose group (12 of 33 participants had a very good partial response or better). Taking safety and activity results together, a target dose of 12 mg was identified as the preliminary RP2D. INTERPRETATION: MK-4002 had manageable safety and clinical activity at doses of 2·15 mg or higher in participants with heavily pretreated relapsed or refractory multiple myeloma. Optimal safety and activity were observed at 12 mg, supporting further clinical evaluation of this dose. FUNDING: Harpoon Therapeutics, a subsidiary of Merck & Co, Rahway, NJ, USA.
引用
- Madan S, Costello C, Lipe B, et al. MK-4002, a B-cell maturation antigen-targeting T-cell engager, in relapsed or refractory multiple myeloma: a first-in-human, open-label, phase 1 study. Lancet Haematol. 2026. PMID: 42838070. doi:10.1016/S2352-3026(26)00228-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。